ZIANA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIANA (ZIANA).
ZIANA is a combination of clindamycin (a lincosamide antibiotic) and tretinoin (a retinoid). Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis. Tretinoin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression to increase epidermal cell turnover and reduce comedone formation.
| Metabolism | Clindamycin is primarily metabolized by the liver via CYP3A4 to active and inactive metabolites. Tretinoin is metabolized in the liver by CYP450 enzymes, primarily CYP2C8 and CYP2C9, and undergoes isomerization and oxidation. |
| Excretion | The clindamycin component is primarily excreted in bile (approximately 85%) as metabolites, with about 10% excreted renally as active drug. The tretinoin component undergoes hepatic metabolism and its metabolites are excreted in urine and feces; less than 1% of topically applied tretinoin is recovered in urine. |
| Half-life | Clindamycin phosphate: terminal half-life following topical application is approximately 2-3 hours after absorption; systemic absorption is minimal. Tretinoin: terminal half-life after topical application is not well defined due to negligible systemic absorption; endogenous tretinoin half-life is about 0.5-2 hours. |
| Protein binding | Clindamycin: approximately 94% bound to plasma proteins (mainly albumin). Tretinoin: >95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Clindamycin: systemic Vd is 0.6-1.2 L/kg; following topical application, systemic absorption is minimal, making Vd clinically irrelevant. Tretinoin: due to negligible systemic absorption, Vd is not applicable. |
| Bioavailability | Topical application: minimal systemic absorption. For clindamycin, approximately 1-6% of the dose is absorbed systemically; for tretinoin, less than 2% is absorbed. |
| Onset of Action | Clinical improvement in acne lesions is typically observed within 2 to 6 weeks of topical application twice daily. |
| Duration of Action | Application twice daily maintains continuous suppression of Propionibacterium acnes and normalization of follicular keratinization; clinical effects persist with regular use. |
One capsule (300 mg clindamycin/75 mg tretinoin) applied topically once daily at bedtime.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required. Clindamycin undergoes hepatic metabolism and renal excretion of inactive metabolites; tretinoin is not renally cleared. However, ensure adequate renal function (eGFR ≥30 mL/min) due to excipient concerns. |
| Liver impairment | No adjustment for mild hepatic impairment (Child-Pugh A). Use with caution in moderate-severe impairment (Child-Pugh B/C) as clindamycin is hepatically metabolized; monitor for adverse effects. |
| Pediatric use | Safety and efficacy not established in pediatric patients <12 years. For ages ≥12 years, same as adult dose (one capsule topically once daily at bedtime). |
| Geriatric use | No specific dose adjustment; use with caution due to potential age-related skin fragility and dryness. Monitor local tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZIANA (ZIANA).
| Breastfeeding | No data on excretion in breast milk. Clindamycin is excreted in human milk in low amounts (M/P ratio not reported for this specific product); tretinoin is not known to be excreted. Caution advised due to potential for adverse effects in nursing infants (e.g., gastrointestinal disturbances with clindamycin). Decision to discontinue breastfeeding or drug should consider importance of drug to mother. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in humans; animal studies show no teratogenic effects at systemic exposures up to 10 times the human dose. Risk cannot be ruled out. Avoid in first trimester unless benefit outweighs risk. In second and third trimesters, use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to clindamycin, tretinoin, or any component of the formulation.","History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis due to clindamycin."]
| Precautions | ["Clindamycin may cause pseudomembranous colitis due to C. difficile overgrowth.","Avoid excessive sun exposure or artificial UV light; use sunscreen.","Avoid application to eczematous or sunburned skin.","Potential for skin irritation, peeling, or redness; reduce frequency if irritation occurs.","Not for oral, ophthalmic, or intravaginal use."] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Monitor for maternal adverse effects, particularly gastrointestinal symptoms (pseudomembranous colitis) and skin reactions. Routine prenatal care is sufficient. |
| Fertility Effects | No known effect on fertility. In animal studies, no impairment of fertility was observed with clindamycin or tretinoin at systemic exposures similar to human topical use. |